Where do you think
$ASTS will finish this year at?
1. Under $20
2. $40
3. $80+
At current levels, are you still adding?
Drop your number below
40
$VKTX (~$27) obesity leader holding $960M cash!
• New ObesityWeek data: 71%+ improved BMI, reversing prediabetes & CVD risks
• 4 Phase 3 trials (weekly injection + oral pill) + Amylin VK3019 Q1'27
• Canaccord $118 PT (avg ~$95+)!
133
$ONDS autonomous defense juggernaut :
• Q3 rev exploded +1,240% YoY ($135.3M) with first-ever GAAP profit ($82.4M) & $1.21B backlog
• Raised 2027 rev goal to $1.5B + $846M cash & $21 PT!
1
62
$FNMA (~$6.04) massive profit & relisting momentum :
• Q3 net income jumped to $4.03B (35th profitable quarter), net worth hit $117.1B
• NYSE relisting filed + new Goldman Sachs Buy ($8.50 PT)!
1
245
$GLND (~$88M cap) Greenland energy breakout :
• Acquiring 80 Mile plc for 100% ownership of its 2M+ acre Jameson Land basin (~13B bbl prospective)
• Expanding into critical minerals & biofuels + Q3 loss narrowed!
2
299
$EOSE 63.07% Short Volume & 1.33M Short Exempt – This isn't fundamentals, it's deliberate price suppression
Look at the FINRA data from yesterday (Nov 17):
📌 Short Volume Ratio: 63.07% (8,203,931 short shares out of 13,007,582 total volume)
📌 Short Exempt Volume (naked illegal short selling): 1,330,893 shares
Sure, the overall market is ugly right now and the Russell 2000 has been dropping for days—and shorts are clearly using that macro weakness as a smokescreen.
But let's be honest: 63% daily short volume and 1.33M exempt shares has nothing to do with fundamentals.
They are deliberately suppressing the price by any means necessary—even waiting until the final 3 minutes before market close to slam it from -7.9% to -12.8% ($1.57) to trigger SSR.
With ~39% official Short Interest already piled on, this level of daily manipulation is completely out of control
246
$VKTX Overall, Jefferies was a bit of a nothing burger, as expected. However, what I take away from it is BL’s communication, which was significantly better and more relaxed today.
At the same time, I felt he was much more straightforward about a partnership being the preferred route.
As mentioned before, there is absolutely nothing in the current hiring activity suggesting that they are building towards GIA. The roles they are currently recruiting for are also roles that could easily be integrated into a partnership structure.
Overall, a positive fireside chat.
84
$NIO Battery swapping is a capital-intensive venture. According to Nio, the construction cost for its first-generation stations was approximately 3 million yuan (400 thousand USD), while second-generation stations cost around 2 million yuan (300 thousand USD). Costs for third- and fourth-generation stations have further decreased to approximately 1.5 million yuan (200 thousand USD).
To date, Nio has invested over 20 billion yuan (3 billion USD) in charging and swapping technology. As of August 12, the company has established a nationwide network of 9,198 charging and swapping stations, including 4,017 swap stations and 5,181 charging stations, supported by 29,875 charging piles. This network has facilitated over 120 million battery swaps and 200 million total charging/swapping services.
52
$SLS
will sls stock short sellers likely see margin calls soon with this cancer breakthrough.
Yes, short sellers holding positions in Sellas Life Sciences (SLS) are highly likely to face immediate and severe margin calls. Following news of a massive clinical breakthrough, SLS stock skyrocketed roughly 150% in pre-market trading to $18.65, after hitting a 52-week high of $24.89.
When a stock gaps up this aggressively overnight, it exponentially expands the liabilities of short positions, triggering automatic risk thresholds at brokerages.
Sellas Life Sciences Group Inc (SLS)
$18.65
149.67% today
As of Nov 18, 6:20 AM CST •
$TE After analyzing T1 Energy’s financials, contracts and SEC filings, here are November’s key developments:
Nov 12 — Demand: Over 3.5 GW contracted for 2027, exceeding 70% of G1 Dallas capacity.💫
Nov 12 — Contracts: 1.58 GW in new supply agreements, including Avantus, for 2027–28.💫
Nov 12 — Financials: Q3 net loss narrowed from $130.8M to $34.7M YoY.💫
Nov 12 — G2 Funding: Institutional debt-financing negotiations ongoing; no final agreement.
Nov 16 — Financial Flexibility: Optional $100M equity facility through Roth Capital supports G2 Austin and working capital. T1 controls issuance timing and volume.
My Assessment: Growing demand, improving financials and manufacturing progress support long-term potential. Financing and dilution remain risks.
231


















